Boas R A, Covino B G, Shahnarian A
Br J Anaesth. 1982 May;54(5):501-5. doi: 10.1093/bja/54.5.501.
The analgesic effect of i.v. lignocaine was evaluated in five patients with clinical neuralgic pain of varying aetiology. The response was compared with that on concurrently-induced ischaemic pain, initially of the same intensity. Following a high dose infusion of 3 mg kg-1 (lignocaine concentrations greater than 3 microgram ml-1) both pains were decreased, clinical pain to a significantly greater extent. Thereafter, at lower doses and blood concentrations, lignocaine was without effect on ischaemic pain, but almost totally suppressed the same patient's clinical pain. The results suggest a divergence in the specificity of the analgesic action of lignocaine i.v. according to the nature of the pain-inducing process. Disorders manifesting as deafferentation or central neuralgias appear to be affected favourably by lignocaine i.v. whereas pain of peripheral origin is unaffected by lignocaine, except at blood concentrations which approach toxic values.
对5例病因各异的临床神经痛患者评估了静脉注射利多卡因的镇痛效果。将其反应与同时诱发的、初始强度相同的缺血性疼痛的反应进行比较。在静脉输注3mg/kg的高剂量（利多卡因浓度大于3μg/ml）后，两种疼痛均减轻，临床疼痛减轻的程度明显更大。此后，在较低剂量和血药浓度下，利多卡因对缺血性疼痛无影响，但几乎完全抑制了同一患者的临床疼痛。结果表明，静脉注射利多卡因的镇痛作用特异性根据疼痛诱发过程的性质而有所不同。表现为传入神经阻滞或中枢性神经痛的疾病似乎受到静脉注射利多卡因的有利影响，而外周源性疼痛不受利多卡因影响，除非血药浓度接近中毒值。
